@sstoneman.bsky.social
🇮🇪 Nephrologist. GN fellow in 🇨🇦.
Thanks Darren. I would caveat that comment by saying it’s a narrative review. Hope you are well, miss our meetings in Cork.
16.02.2026 01:00 — 👍 2 🔁 0 💬 0 📌 0
Excited about this @theisn.org initiative, especially under the leadership of @hswapnil.medsky.social as EIC. Nephrology needed this
www.theisn.org/blog/2025/12...
Yes. This is a game changer. Beyond being able to replace AVS, it allows one to “see” the underlying pathological contributors to a large proportion of “idiopathic” hypertension. This is another piece of evidence that should make clinicians rethink the pathogenesis and treatment of hypertension
28.11.2025 18:05 — 👍 9 🔁 4 💬 0 📌 0Ok, we have a winner. Thanks. bsky.app/profile/matt...
27.11.2025 07:42 — 👍 13 🔁 1 💬 0 📌 02025 @thelancet.com #CKD seminar out! Read it for latest evidence on how to manage what is projected to become a top
5 leading cause of death globally by 2050 (read it so in 25years’ time that does not happen…):
www.sciencedirect.com/science/arti...
I think Aliza Thompson is an unsung hero in this story for spearheading the albuminuria acceptance at FDA
journals.lww.com/cjasn/pages/...
#NephJC
Sinead, current GN fellow.
Exciting times in IgAN/nephrology in general. No COI.
Mainly lurking tonight.
#NephJC
Clinical Variability of ADPKD in Monozygotic Twins www.kireports.org/article/S246...
15.11.2025 14:50 — 👍 11 🔁 3 💬 0 📌 0
Figure 1 ADAPT steps. CHW, community health worker; CSC, community steering committee.
And paper 3 from @cervantes-lily1.bsky.social
On adaptation of the Navigate Kidney intervention in @kireports.bsky.social
www.kireports.org/article/S246...
#KidneyWk
And the GBD analysis on CKD
From @paddymark.bsky.social and colleagues
www.thelancet.com/journals/lan... in @thelancet.com
#KidneyWk
Visual abstract
Trials coming out already!
jamanetwork.com/journals/jam...
Rituximab better than placebo in FRNS/SDNS
Duh.
#KidneyWk #NephSky
Another simultaneous publication from the afternoon session
Albuminuria as an acceptable surrogate outcome (per our discussion earlier today)
www.nature.com/articles/s41... in @naturemedicine.bsky.social @nature.com sadly paywalled
#KidneyWk
American Society of Nephrology Kidney Week 2025 Original Article | Nov. 6, 2025 | NEJM.org A Phase 3 Trial of Atacicept in Patients with IgA Nephropathy Figure 2A. Change from Baseline in 24-Hr Urinary Protein-to-Creatinine Ratio through Week 36. The NEJM identity sits at the bottom.
ORIGIN phase 3 trial: In an interim analysis of a clinical trial, atacicept, a fusion protein that binds and inhibits two cytokines thought to be central to the pathophysiology of IgA nephropathy, significantly reduced proteinuria. nej.md/3JEq8QL
@asnkidney.bsky.social | #KidneyWk
JAMA Clinical Guidelines Synopsis: Classification and Risk Assessment of Chronic Kidney Disease. Guideline Title: KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease.
The KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease recommends using equations that include both creatinine and cystatin C for more accurate GFR estimation and risk assessment in CKD.
ja.ma/43QS5vy
I like to lump patients with type IV collagen variants into 4 main categories that can help predict risk of progression and recommended treatment. #KidneyWk
06.11.2025 18:39 — 👍 6 🔁 4 💬 1 📌 0
Highlights from my talk yesterday on Alport syndrome spectrum of disorders. (since no one posted it, I'll have to do it myself)
Variants in type IV collagen cause a wide spectrum of disease. #KidneyWk 🧵
watch out - ORIGIN-3 and FINEONE
likely simultaneous publications tomorrow morning!
#KidneyWk
Fantastic Day 1 ✅ #KidneyWk @asnkidney.bsky.social
05.11.2025 23:36 — 👍 2 🔁 1 💬 0 📌 0Idea for a Christmas BMJ paper: submit loads of Christmas BMJ papers, then do a survival analysis of time to rejection. Then submit the survival analysis as a Christmas BMJ paper the following year
29.10.2025 10:05 — 👍 16 🔁 3 💬 2 📌 0
Crescents at various stages of maturation (cellular, fibrocellular, fibrous):
23.11.2024 00:36 — 👍 17 🔁 9 💬 0 📌 0I’m Sinead and I “have a faulty amygdala”. As per a neurologist I worked for.
23.11.2024 01:38 — 👍 4 🔁 0 💬 0 📌 0This is amazing. Amazing. Fair play @hswapnil.bsky.social et al.
My vote for nephrology story of the year.
There we are! Right alongside journalists and Pokemon fans!
@hswapnil.bsky.social killing it!
“Patients who are diagnosed with ACE inhibitor-induced angioedema should be tested for hereditary angioedema types 1/2“
So far, not something that I have been doing …
#whatilearnedtoday #nephsky #skyneph
onlinelibrary.wiley.com/doi/10.1111/...
❄️🌬" Snow White Tales in Nephrology" ❄️
💥Our latest article collects evidences from the published literature between skin whitening creams and glomerular diseases. 🌟 🩺
https://buff.ly/3CBzGIy
📢
Our systematic review published in BMC Nephrology examines the potential of continuous glucose monitoring (CGM) in improving glycemic control for patients with diabetes and the challenges of managing blood glucose levels in this unique population and highlights promising results from CGM use.
What about adjusting for follower count?
21.11.2024 14:58 — 👍 2 🔁 0 💬 0 📌 0
Still very cool to sit in grand rounds and see a #VisualAbstract after #VisualAbstract make it into the slide deck.
Hard to underestimate how much good science AND good design helps dissemination.
#medsky
Just landed here! Looks very good. Happy to meet so many known faces here.
20.11.2024 19:39 — 👍 15 🔁 1 💬 1 📌 0#NephJC comment from EP specialist on the significance of CSCA
See @christosargyrop.bsky.social even asystolic pauses are seemingly common 😳
